Resistant disease is still a main obstacle in acute myeloid leukemia (AML) treatment. Therefore, individual genetic variations affecting therapy response are gaining increasing importance. Both SNPs and ABC transporter genes could already be associated with drug resistance. Here, we report allelic variants of MRP1 (ABCC1) SNPs rs129081, rs212090, and rs212091 with significant influences on survival in AML patients. DNA was extracted from bone marrow samples (n = 160) at diagnosis. Genotyping 48 SNPs within seven different ABC transporter genes using real-time PCR revealed rs129081 GG variant with a significant higher OS (p = 0.035) and DFS (p = 0.01). Comparing TT and AA rs212090 variants showed significant influences on DFS (p = 0.021). SNP rs212091 GG expression was associated with worse OS (p = 0.006) and a significant difference in DFS between alleles GG and AA (p = 0.018). The multivariable models confirmed a significant influence on OS for rs212091 (AA HR = 0.296, 95% CI 0.113–0.774, p = 0.013 and GG p = 0.044). Rs129081 variant CG, TT of rs212090, AA, and AG of rs212091 demonstrated significant impact on DFS (p = 0.024, p = 0.029, p = 0.017, and p = 0.042, respectively). This analysis demonstrates a significant influence of MRP1 SNPs on survival in AML. As they were not associated to prognostic characteristics, we suggest these SNPs to be independent prognostic markers for AML.

抗药性疾病仍然是急性髓细胞性白血病（AML）治疗的主要障碍。因此，影响治疗反应的个体遗传变异变得越来越重要。SNP和ABC转运蛋白基因可能已经与耐药性相关。在这里，我们报告了MRP1（ABCC1）SNP rs129081，rs212090和rs212091的等位变体，它们对AML患者的存活率有重大影响。 诊断时从骨髓样本（n = 160）中提取DNA 。使用实时PCR对七个不同ABC转运蛋白基因中的48个SNP进行基因分型显示rs129081 GG变异体具有显着更高的OS（p  = 0.035）和DFS（p = 0.01）。比较TT和AA rs212090变体显示出对DFS的显着影响（p  = 0.021）。SNP rs212091 GG表达与OS恶化（p  = 0.006）和等位基因GG与AA之间的DFS显着差异（p  = 0.018）相关。多变量模型证实了对rs212091的OS的显着影响（AA HR = 0.296，95％CI 0.113-0.774，p  = 0.013和GG p  = 0.044）。Rs129081变体CG，rs212090的TT，AA和rs212091的AG对DFS表现出显着影响（分别为p  = 0.024，p  = 0.029，p  = 0.017和p  = 0.042）。该分析表明了MRP1 SNP在AML中的存活率。由于它们与预后特征无关，因此我们建议这些SNP是AML的独立预后标志物。